Open Access Maced J Med Sci. 2020 Oct 21; 8(B):1005-1009. 1005 Scientifc Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2020 Oct 21; 8(B):1005-1009. https://doi.org/10.3889/oamjms.2020.5424 eISSN: 1857-9655 Category: B - Clinical Sciences Section: Infective Diseases Efcacy of 24-week Administration of Tenofovir Disoproxil Fumarate in the Management of Naïve Chronic Hepatitis B Darmadi Darmadi, Gontar Alamsyah Siregar* Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia Abstract BACKGROUND: Chronic hepatitis B (CHB) is becoming a common liver abnormality worldwide. Thus, a series of good management is needed to prevent the progression and complications of hepatitis B infection. Tenofovir disoproxil fumarate (TDF) is one of the drugs of choice that’s used for CHB management. AIM: Limited studies were found regarding the efcacy of tenofovir in dealing with CHB. Hence, the aim of this study is to determine the efcacy of TDF administration for 24 weeks in subjects with naïve CHB in Medan, Indonesia. METHODS: Retrospective study was conducted in Haji Adam Malik Hospital Medan, Indonesia, between January and December 2019. Subjects were CHB patients aged 18 years or older and were treated TDF for 24 weeks. Demographic, clinical, and CHB disease progression parameters (serum alanine aminotransferase [ALT], hepatitis B envelope antigen [HBeAg], and hepatitis B virus deoxyribonucleic acid [HBV DNA]) data were obtained. RESULTS: One hundred and twenty subjects were obtained and divided into 2 groups: HBeAg positive and HBeAg negative. Mean age of subjects was 46.5 ± 10.36 years in HBeAg positive group and 48.6 ± 10.67 years HBeAg negative group, with predominant males’ subjects in both groups (58.3% vs. 61.7%, respectively). Serum ALT normalization and undetectable serum HBV DNA were observed in more than 70% and 65% of subjects in both groups, respectively (both p < 0.001). Serum HBeAg loss was achieved in 10.8% subjects (p < 0.001). No subject showed serum HbsAg loss. CONCLUSION: Our results are consonant with current clinical guidelines and other evidence literature. For both HBeAg-positive and HBeAg-negative populations, TDF administration for 24 weeks has good efcacy in naïve CHB patients. Edited by: Slavica Hristomanova-Mitkovska Citation: Darmadi D, Siregar GA. Efcacy of 24-week Administration of Tenofovir Disoproxil Fumarate in the Management of Naïve Chronic Hepatitis B. Open Access Maced J Med Sci. 2020 Oct 21; 8(B):1005-1009. https://doi.org/10.3889/oamjms.2020.5424 Keywords: Chronic hepatitis B; Efcacy; HBeAg; HBV DNA; Tenofovir disoproxil fumarate *Correspondence: Gontar Alamsyah Siregar, Dr. Mansyur 5, Medan, Indonesia, E-mail: gontarsir@gmail.com Received: 06-Sep-2020 Revised: 10-Oct-2020 Accepted: 11-Oct-2020 Copyright: © 2020 Darmadi Darmadi, Gontar Alamsyah Siregar Funding: This research did not receive any fnancial support Competing Interests: The authors have declared that no competing interests exist. Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution- NonCommercial 4.0 International License (CC BY-NC 4.0) Introduction Hepatitis B virus, also known as HBV, is a double-stranded deoxyribonucleic acid (DNA) virus from the hepadnavirus family that causes acute and chronic liver infections in human [1]. From the epidemiological perspective, the highest prevalence of CHB is reported in Africa and Asia [2]. According to Baseline Health Research, the prevalence of Hepatitis B in Indonesia increased from 0.2% in 2013 to 0.4% in 2018 [3]. Although the coverage for early detection and immunization for hepatitis B has always reached the target until 2017 [4], Indonesia is still categorized as a moderate-to-highly endemic region for HBV infection [5]. The majority cases of Hepatitis B can progress to chronic liver disease, with the chronicity depends on the time exposure to hepatitis B virus (HBV) [6]. If left untreated, the disease can lead to fatal complications, including cirrhosis, liver failure, and hepatocellular carcinoma [6], [7], [8]. In fact, after 5 years of sufering from CHB, the risk of developing hepatocellular carcinoma increases up to 17% in Eastern countries compared to 10% in western countries. The 5-year survival rate for patients with decompensated liver cirrhosis due to HBV is 17–35% [9]. Thus, a series of good management is needed to prevent the progression and complications of Hepatitis B infection. There are many diferent treatment options available. Treatments that are used in CHB management are peginterferon-alpha, lamivudine (LMV), adefovir (ADV), telbivudine, entecavir (ETV), and tenofovir (TDF) [7]. Several parameters are used to monitor CHB progression such as serum alanine aminotransferase (ALT) level, HBV DNA level, antigens specifc to HBV, and histopathological examination [1], [7], [10], [11]. Viral suppression, ALT normalization, absence of viral resistance, HBeAg loss, HBsAg seroconversion, and liver histology improvement are the short-term goals regarding with CHB infection [1]. Furthermore, the long-term aims of management of CHB are to improve survival rate and to prevent complications [2], [9], [10]. Moreover, the treatment for this condition may need to be lifelong, thus the drugs used must be both efcacious and safe [11]. TDF is one of the nucleotide analogue drug that is used as the frst-line treatment of CHB [8], [12, [13], [14].